All news

30 September 2026

Patients who swapped weight-loss shots for Novo's Wegovy pill lost more weight

Novo Nordisk shared real-world data showing people who moved from weekly injections to its Wegovy pill lost about 4% more body weight over three months.

Weight-loss drugs have mostly meant weekly shots. On Wednesday, Novo Nordisk showed early data suggesting that people who moved from those shots to its new Wegovy pill kept losing weight, rather than just holding steady.

What happened

Novo presented an analysis of 194 patients on the telehealth platform Ro, all of them living with obesity or overweight. Half had started on Novo's Wegovy injection and half on Eli Lilly's Zepbound shot before switching to the pill.

Those who stayed on the pill for three months lost roughly 4% more of their body weight, or an average of 8.8 pounds extra, from an average starting weight of about 221 pounds. Two in five reached 5% or more weight loss after the switch. The share with a body mass index (BMI, a height-to-weight measure) of 30 or higher, the threshold for obesity, fell by more than 21%.

Patient feedback was positive too. About 75% said they were satisfied with the switch, and around 82% reported at least one improvement, such as clothes fitting better.

Why it matters

Novo's chief scientific officer, Martin Holst Lange, said the company now sees a clear preference for pills. Shots can need refrigeration, which is a nuisance for frequent travelers.

There are big caveats, and Novo listed several itself. This is a real-world study, so it shows associations and cannot prove the pill caused the extra weight loss. It has no control group, the data comes from routine telehealth care and is partly self-reported, and Novo says the results are not generalizable to the broader population. Treat it as a first signal, not a verdict.

The company also presented other data at a European diabetes meeting in Milan. Its experimental drug CagriSema, a mix of semaglutide (the active ingredient in Wegovy) and a drug called cagrilintide, reduced "food noise", meaning persistent thoughts about food, in a year-long brain imaging study. Novo says CagriSema is expected to launch early next year.

What to watch

  • Larger, controlled studies of people switching from shots to the pill.
  • How many patients stay on the pill beyond three months.
  • The expected early-2027 launch of CagriSema, with a higher-dose version and standalone cagrilintide due in 2028.

Novo's share price and financials are on its Noorult company page.

The companies in this story

Based on reporting by CNBC: People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study. Facts, not advice.

More news